CI β€” CIGNA CORP COM

Ownership history in ORBIMED ADVISORS LLC  Β·  39 quarters on record

This page tracks every 13F SEC filing in which ORBIMED ADVISORS LLC reported a position in CIGNA CORP COM (CI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
2.49% (2017 Q4)
πŸ“Š Avg. % of fund
0.89%
πŸ“… First filed
2009 Q2
πŸ“… Last filed
2025 Q4
⏱ Quarters held
39

Position Intelligence

ORBIMED ADVISORS LLC Γ— CI AI Analytics

πŸ“ˆ ORBIMED ADVISORS LLC outperformed the S&P 500 by +5.7% annually on this CI position. Timing score: 64% (21/33 decisions correct). Average cost basis: $107.87. Maximum drawdown during holding period: –27.1%.

πŸ“ˆ Position Alpha vs SPY
+5.7%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 5.7% per year on this position.
38 quarters analyzed

⏱️ Timing Score
64%

βœ… Decent timing β€” more right than wrong on entries and exits.
21 of 33 add/trim decisions correct

πŸ’° Entry Quality
$107.87
+153.7% vs current ($273.72)

Best entry: $21.79 (2009 Q2)  Β·  Worst: $273.72 (2025 Q4)

πŸ›‘οΈ Drawdown Resilience
–27.1%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
56%
buy-side decisions

19 adds Β· 15 trims. Bought during 5 of 12 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
β†’ Stable
last 4–5 quarters trend

βš–οΈ Portfolio weight has remained relatively stable β€” conviction maintained.
Currently 1.15% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    CI price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 205,000 +42,200 +25.9% 1.15% $56.4M $273.72
2025 Q3 REDUCED 162,800 -68,700 -29.7% 1.10% $46.9M $285.07
2023 Q3 ADDED 231,500 +70,500 +43.8% 1.41% $66.2M $272.98
2023 Q2 REDUCED 161,000 -278,700 -63.4% 0.82% $45.2M $266.57
2020 Q2 UNCHANGED 439,700 β€” 0% 1.16% $82.5M $170.73
2020 Q1 REDUCED 439,700 -50,000 -10.2% 1.31% $77.9M $161.20
2019 Q4 ADDED 489,700 +198,100 +67.9% 1.43% $100.1M $186.01
2019 Q3 ADDED 291,600 +39,000 +15.4% 0.84% $44.3M $138.08
2019 Q2 UNCHANGED 252,600 β€” 0% 0.62% $39.8M $143.32
2019 Q1 REDUCED 252,600 -230,100 -47.7% 0.63% $40.6M $146.29
29 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

🏒 Other funds also holding CI

As of 2025 Q4 β€” sorted by position size

TAM Capital Management Inc. 3Y 7Y 21.61% Brummer Multi-Strategy AB 19.66% BloombergSen Inc. 3Y 7Y 19.54% 53 HOUSE LLP 3Y 7Y 10.06% Seven Springs Wealth Group, LLC 3Y 9.77% BOONE CAPITAL MANAGEMENT LLC 3Y 8.33% Sio Capital Management, LLC 3Y 7Y 7.46% LAKEWOOD CAPITAL MANAGEMENT, LP 3Y 7Y 7.38% BANYAN CAPITAL MANAGEMENT, INC. 3Y 7Y 7.19% Focused Investors LLC 3Y 7Y 6.21%
← Back to ORBIMED ADVISORS LLC Holdings